In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.
In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.
On this episode of TWiV, the observation that the 1918 influenza virus is not lethal in nonhuman primates and implications for studies on viral virulence, and mRNA vaccines that control and resolve human papillomavirus-associated cancers in mice.
In his weekly clinical update Dr. Griffin discusses confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era, the effectiveness of maternal Influenza vaccination in Peru, characteristics and predictors of persistent symptoms post-COVID-19 in children and young people, parental nonadherence to health policy recommendations for prevention of COVID-19 transmission among children, community-onset bacterial coinfection in children critically ill with SARS-CoV-2 infection, bivalent booster effectiveness against severe COVID-19 outcomes in Finland, viral kinetics of sequential SARS-CoV-2 infections, risk of COVID-19 associated Pulmonary aspergillosis based on corticosteroid duration in intensive care patients, immunomodulators for severe COVID19 in transplant patients: do they increase the risk of secondary infection, long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population, cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection, one-year adverse outcomes among us adults with Post–COVID-19 condition vs those without COVID-19 in a large commercial insurance database, and long-term gastrointestinal outcomes of COVID-19.
TWiV to explains a study on presence of COVID-19 vaccine mRNA in the blood, and the isolation of cross-protective monoclonal antibodies against common endemic respiratory viruses.
In his weekly clinical update Dr. Griffin discusses FDA authorizing the first over-the-counter at-home test to detect both influenza and COVID-19, monoclonal antibody for the prevention of respiratory syncytial virus infection in infants and children, epidemiologic characteristics of SARS-CoV-2 recombinant variant XBB.1.5, COVID-19 vaccines vs pediatric hospitalization, maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children, fatal fulminant cerebral edema in six children with SARS-CoV-2 Omicron BA.2 infection in Taiwan, certifying deaths due to COVID-19, efficacy of first dose of COVID-19 vaccine vs no vaccination on symptoms of patients with long COVID, and the effect of COVID-19 vaccination on long COVID.
Arturo Casadevall returns to TWiV to explain the use of convalescent plasma to treat COVID-19 patients, and the need to support virology at a time when more regulation of experiments is envisioned.
In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC’s long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity.
TWiV reviews an outbreak of Marburg hemorrhagic fever in Equatorial Guinea, wild poliovirus type 3 shedding from a laboratory in the Netherlands, and white-tailed deer as a reservoir for previous SARS-CoV-2 variants of concern.